病人自己用不受管制的原料制造肥胖药物,由于缺乏监督,费用高昂,因此健康面临风险。 Patients are making their own obesity drugs from unregulated raw ingredients, risking health due to lack of oversight and high costs.

病人越来越多地转向灰色市场购买生药原料,通常从中国购买,在高昂费用和保险覆盖面有限的情况下,自己制造肥胖症药物。 Patients are increasingly turning to the gray market to buy raw drug ingredients—often from China—to make their own obesity medications, driven by high costs and limited insurance coverage. 这种不受管制的做法造成了严重的健康风险,包括污染、误用剂量和缺乏质量控制,因为这些自制药物未经林业发展局批准或检验。 This unregulated practice poses serious health risks, including contamination, incorrect dosing, and lack of quality control, as these self-made drugs are not approved or tested by the FDA. 尽管卫生专家警告, 由于获得FDA批准的治疗方法的负担能力差距, 需求仍在持续. Despite warnings from health experts, demand persists due to the affordability gap in accessing FDA-approved treatments.